Persistent SARS‐CoV‐2 RNA Positivity in a Chronic Lymphocytic Leukaemia Patient for 127 Days After Disease Onset: A Case Report
- 1Department of Infectious Diseases and Tropical Medicine, Imam Hossein Hospital, School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran
- 2Department of Critical Care Nursing, School of Nursing and Midwifery Tehran University of Medical Sciences Tehran Iran
Abstract
Chronic lymphocytic leukaemia (CLL) is characterised by profound immune dysfunction, increasing susceptibility to severe and persistent infections such as COVID‐19. Our case report presents a 69‐year‐old woman with CLL who exhibited a prolonged duration of SARS‐CoV‐2 RT‐PCR positivity—127 days—despite receiving standard therapies including dexamethasone and remdesivir. The patient, previously on maintenance ibrutinib, presented with fever and ground‐glass opacities on CT scan and laboratory findings revealed marked lymphocytosis, elevated inflammatory markers and hepatic and renal dysfunction. Persistent viral shedding was attributed to CLL‐associated hypogammaglobulinemia and chemotherapy‐induced immunosuppression, resulting in impaired antibody response and eventual fatal hypoxemia. This case underscores the challenges of managing COVID‐19 in CLL patients and highlights the need for individualised treatment strategies, including consideration of monoclonal antibodies and immunoglobulin replacement, to address prolonged viral replication and improve clinical outcomes in this vulnerable population.
Related
- Aplastic Anaemia in a Chronic Lymphocytic Leukaemia Patient Treated With Acalabrutinib, a Bruton Tyrosine Kinase Inhibitor—Case Report
- Richter Transformation of Chronic Lymphocytic Leukaemia: Biology, Diagnosis, and an Evolving Therapeutic Landscape
- USP7 inhibits FOXO1 activity in chronic lymphocytic leukaemia cells enhancing cell survival.
- Economic Burden of Chronic Lymphocytic Leukaemia in Australia
- Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups
BibTeX
@article{khamseh2026persistent,
title = {{Persistent SARS‐CoV‐2 RNA Positivity in a Chronic Lymphocytic Leukaemia Patient for 127 Days After Disease Onset: A Case Report}},
author = {Farnoosh Khamseh and Amir‐Hossein Moghtader‐Mojdehi and Zahra Nemati and Mehrdad Haghighi},
journal = {Respirology Case Reports},
year = {2026},
month = oct,
doi = {10.1002/rcr2.70767},
url = {https://doi.org/10.1002/rcr2.70767},
note = {CC BY},
}
RIS
TY - JOUR
TI - Persistent SARS‐CoV‐2 RNA Positivity in a Chronic Lymphocytic Leukaemia Patient for 127 Days After Disease Onset: A Case Report
AU - Farnoosh Khamseh
AU - Amir‐Hossein Moghtader‐Mojdehi
AU - Zahra Nemati
AU - Mehrdad Haghighi
PY - 2026
DA - 2026/10/28
JO - Respirology Case Reports
DO - 10.1002/rcr2.70767
UR - https://doi.org/10.1002/rcr2.70767
AB - Chronic lymphocytic leukaemia (CLL) is characterised by profound immune dysfunction, increasing susceptibility to severe and persistent infections such as COVID‐19. Our case report presents a 69‐year‐old woman with CLL who exhibited a prolonged duration of SARS‐CoV‐2 RT‐PCR positivity—127 days—despite receiving standard therapies including dexamethasone and remdesivir. The patient, previously on maintenance ibrutinib, presented with fever and ground‐glass opacities on CT scan and laboratory findings revealed marked lymphocytosis, elevated inflammatory markers and hepatic and renal dysfunction. Persistent viral shedding was attributed to CLL‐associated hypogammaglobulinemia and chemotherapy‐induced immunosuppression, resulting in impaired antibody response and eventual fatal hypoxemia. This case underscores the challenges of managing COVID‐19 in CLL patients and highlights the need for individualised treatment strategies, including consideration of monoclonal antibodies and immunoglobulin replacement, to address prolonged viral replication and improve clinical outcomes in this vulnerable population.
SN - 2051-3380
ER -